Management of lennox-gastaut syndrome with rufinamide

Batool F. Kirmani, Diana Mungall, Jose Aceves

Research output: Contribution to journalArticlepeer-review


Lennox-Gastaut syndrome (LGS) is a pediatric epileptic encephalopathy, which is characterized by uncontrolled seizures, diffuse slow spike and wave discharges on encephalogram, and cognitive impairment. This is a severe form of childhood epilepsy, pharmacoresistant in most cases, with a peak incidence between the ages of 3 and 5 years. Mental retardation is common attributed to increased frequency of seizures. Rufinamide approval by Food and Drug Administration gave new hope to patients and their caregivers. Rufinamide is a third generation anticonvulsant, which is structurally different from other anticonvulsants. Clinical trials of rufinamide have shown a decreased frequency of seizures including atonic seizures and drop attacks in patients with LGS. In this current paper, we discuss the role of rufinamide as a new option in the management of this childhood epileptic encephalopathy.

Original languageEnglish (US)
Pages (from-to)109-113
Number of pages5
JournalJournal of Pediatric Epilepsy
Issue number2
StatePublished - Jan 1 2013
Externally publishedYes


  • Anticonvulsants
  • Epileptic encephalopathy
  • Lennox-gastaut syndrome
  • Rufinamide

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Clinical Neurology


Dive into the research topics of 'Management of lennox-gastaut syndrome with rufinamide'. Together they form a unique fingerprint.

Cite this